Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
在加速推进的迷幻疗法和药物研发扩张中，生物制药公司Cybin报告损失7800万美元。
Cybin Inc. (AMEX:CYBN) (CBOE: CYBN), a clinical-stage biopharmaceutical company focused on developing next-generation psychedelic treatments for mental health disorders, announced Wednesday its financial results for the fiscal quarter and year ending March 31, 2024, alongside significant strides in psychedelic therapy development. Cybin reported a net loss of C$78 million ($57 million) for FY 2024, a noticeable increase from C$47 million the previous year.
临床阶段生物制药公司Cybin Inc.（AMEX: CYBN）（CBOE: CYBN）专注于开发下一代治疗心理健康障碍的致幻药物治疗，周三宣布其2024财年和截至2024年3月31日的财务业绩，以及在致幻疗法开发方面取得的重要进展。Cybin宣布2024财年净亏损达7800万加元（5700万美元），较上一年的4700万加元有显著增长。
Fiscal Year 2024 Financial Highlights
2024财年财务亮点
No profits or revenues reported.
Net loss was C$78 million.
Cash totaled C$209 million as of March 31, 2024.
Closed oversubscribed private placement of $150 million led by a syndicate of leading biopharmaceutical institutional investors.
没有利润或收入报告。
净损失为7800万加元。
截至2024年3月31日，现金总额为2.09亿加元。
由一群领先的生物制药机构投资者牵头，完成了1.5亿美元的私募定向增发，认购超额。
Q4 2024 Financial Highlights...
20...
登录免费看全文
登录/注册